[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-360313-105":59,"doc-detail-360313-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","consideration-of-enrollment-rates-of-asian-asian-pacific-islander-and-hispanic-patients-in-non-small-cell-lung-cancer-trials","Consideration of Enrollment Rates of Asian, Asian Pacific Islander, and Hispanic Patients in Non-small Cell Lung Cancer Trials","","Efforts to broaden diversity in clinical trials have not eliminated the persistent underrepresentation of Asian, Asian Pacific Islander, and Hispanic patients. This editorial highlights key barriers that limit equitable enrollment in non-small cell lung cancer (NSCLC) trials and proposes strategies to improve representation. Adult patients from these groups are enrolled at substantially lower rates than White patients, despite NSCLC’s high mortality and the presence of ethnically varying cancer-driving mutations. Emphasis is placed on improving trial reporting and recruitment equity to support more generalizable outcomes.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/consideration-of-enrollment-rates-of-asian-asian-pacific-islander-and-hispanic-patients-in-non-small-cell-lung-cancer-trials/360313/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/consideration-of-enrollment-rates-of-asian-asian-pacific-islander-and-hispanic-patients-in-non-small-cell-lung-cancer-trials/360313.png","ImageObject",300,407,{"name":92,"@type":93},"Stanley","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What patient groups remain underrepresented in non-small cell lung cancer trials?","Question",{"text":112,"@type":113},"Asian, Asian Pacific Islander, and Hispanic adult patients remain significantly underrepresented compared with White counterparts in NSCLC clinical trials.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why does improving enrollment equity matter in NSCLC?",{"text":117,"@type":113},"NSCLC has high mortality, and cancer-driving mutations differ among ethnic and racial groups, so equitable enrollment is important for generating more generalized clinical outcomes.",{"name":119,"@type":110,"acceptedAnswer":120},"What kinds of barriers affect minority patient recruitment and enrollment?",{"text":121,"@type":113},"The text highlights socioeconomic, structural, and cultural barriers that can influence long-term informed decision-making and reduce minority participation.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},360313,1790386748,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":24,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},2336477405376,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Targeted Oncology (2026) 21:309–313  \n[https://doi.org/10.1007/s1](https://doi.org/10.1007/s1) 1523-026-01218-z  \nConsideration of Enrollment Rates of Asian, Asian Pacific Islander, and Hispanic Patients in Non‑small Cell Lung Cancer Trials  \nVinay Nittur1 · Cathleen J. Park1 · Misako Nagasaka1,2  \nPublished online: 30 April 2026 © The Author(s) 2026  \nAbstract  \nDespite efforts over the last decade by clinical investigators and organizations to enhance diversity in clinical trials, significant underrepresentation of Asian, Asian Pacific Islander, and Hispanic patients remains an issue. Our editorial highlights key barriers to achieving equity in clinical trial enrollment among patients with non-small cell lung cancer (NSCLC) along with strategies to improve diversity to ensure more generalized clinical outcomes.  \nPlain Language Summary  \nAdult Asian, Asian Pacific Islander, and Hispanic patients with non-small cell lung cancer (NSCLC) are enrolled at much lower rates compared with their white counterparts. Given the high mortality of NSCLC and mutations that drive cancer growth that are different among ethnic/racial groups, it is crucial to improve equity in clinical trial enrollment.  \nKey Points  \nAsian, Asian Pacific Islander, and Hispanic adult patients with non-small cell lung cancer are significantly underrepresented in clinical trials, and current data on enrollment demographics obscure the full extent of these disparities.  \nSocioeconomic, structural, and cultural barriers uniquely affect these patient populations that lead to long-term effects on informed clinical decision-making.  \nOur editorial highlights strategies on disaggregated race and ethnicity data, community engagement options, and enrollment measures for enrollment sites to achieve equitable minority patient recruitment.  \n* Misako Nagasaka [nagasakm@hs.uci.edu](nagasakm@hs.uci.edu)  \n1 University of California Irvine School of Medicine, 101 The City Drive, Orange, CA 92868, USA  \n2 St. Marianna University School of Medicine, Kawasaki, Japan  \n1 Introduction  \nNon-small cell lung cancer (NSCLC) accounts for nearly 83–87% of lung cancers worldwide and remains the leading cause of cancer-related mortality among adult patients [1, 2] . Asian, Asian Pacific Islander (API), and Hispanic patient populations account for a large proportion of adult patients with NSCLC. Studies have identified increasing rates of NSCLC of approximately 1–2% per year amongst Asian and API patients, particularly evident in subgroups of women and nonsmokers [3, 4] .  \nThe treatment landscape of NSCLC, including the emergence of bispecific antibodies, novel ADCs, and targeted therapies, has made rapid advancements for subsets of patients with NSCLC [5] . Despite these advancesand increasing diversity in the USA among patients with NSCLC, enrollment rates of Asian, API, and Hispanic patients into clinical trials remain disproportionately low [6] .  \nThe underrepresentation of minority populations in clinical trials persists in comparison with real-world incidence rates despite evidence highlighting the higher prevalence of driver mutations such as EGFR, ALK, and ROS1 in Asian populations [7, 8] . These important driver mutations are the target of several practice-changing targeted therapies and an example of the biologic diversity that may be masked.  \nWe aim to highlight the magnitude of discrepancies in trial enrollment, identify key barriers to equity in clinical trial enrollment, and explore strategies to improve diversity to ensure more generalized clinical trial outcomes for patients with NSCLC in the USA. We focused on Asian, API, and Hispanic patient populations who face enrollment underrepresentation that is further obscured by data aggregation techniques in clinical trial reporting.  \n2 Enrollment Data and Disparities  \nDespite efforts to increase rates of minority patient participation in US lung cancer clinical trials, Hispanic patients with NSCLC represent only 3.4% of tr","cbCaicbGAEXzVMwF","https://ap.wps.com/l/cbCaicbGAEXzVMwF","pdf",795609,"English","# Abstract\n## Plain Language Summary\n## Key Points\n## Introduction\n## Enrollment Data and Disparities","[{\"question\":\"What patient groups remain underrepresented in non-small cell lung cancer trials?\",\"answer\":\"Asian, Asian Pacific Islander, and Hispanic adult patients remain significantly underrepresented compared with White counterparts in NSCLC clinical trials.\"},{\"question\":\"Why does improving enrollment equity matter in NSCLC?\",\"answer\":\"NSCLC has high mortality, and cancer-driving mutations differ among ethnic and racial groups, so equitable enrollment is important for generating more generalized clinical outcomes.\"},{\"question\":\"What kinds of barriers affect minority patient recruitment and enrollment?\",\"answer\":\"The text highlights socioeconomic, structural, and cultural barriers that can influence long-term informed decision-making and reduce minority participation.\"}]","Consideration of Enrollment Rates of Asian, Asian Pacific Islander, and Hispanic Patients in Non-small Cell Lung Cancer Trials | PDF",1790139576,13,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/378fe3aca61a3165d60fc195903b1574.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ab5fc5684dfa60baeecae9e5e3df4aaf.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8f976a759586fb936f18fd82f30fff53.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e27b996c6e32b863181ef931075ea774.webp",980,1301]